Cost Effectiveness of Serotesting before Hepatitis Vaccination

Publisher Website
Google Scholar
Abstract
To the Editor: One reason that the hepatitis B vaccine has been somewhat slow in appearing on the market is that the manufacturing company has been trying to stockpile enough of it to meet the huge anticipated initial demand. When the vaccine becomes available, many persons (medical, laboratory, and dental personnel; spouses or partners of hepatitis B carriers; homosexuals; parenteral-drug users; patients requiring many transfusions of blood products, travelers to areas of high endemicity of hepatitis B; and others) will undergo serologic tests for hepatitis B, and if negative they will rush to queue up to receive the vaccine. One . . .

This publication has 0 references indexed in Scilit: